SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.

Other languages Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Delayed Hong Kong S.E. Other stock markets 01:38:11 08/05/2024 pm IST			5-day change	1st Jan Change
2.05 ^HKD	-5.96%		-2.84%	-40.06%

25/03	Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor	31/23/31
Shanghai Bio-heart Biological Technology's Loss Narrows in H1	14/23/14
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11
Bioheart Announces Clinical Result for Iberis-Htn At Cit 2023	30/23/30
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Management Changes	26/23/26
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Achievement of Primary Clinical Endpoint in the Iberis-HTN	11/23/11
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Ji Chen Would Not Offer Himself for Re-Election as A Non-Executive Director	31/23/31
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31
Shanghai Bio-heart Biological Technology Co., Ltd. Announces First Patient Enrollment in the RADIUS-HTN Trial	27/23/27
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Clinical Trial of Sirolimus Drug-Eluting Balloon for the Treatment of In-Stent Restenosis	18/22/18
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Its Iberis® multi-electrode RDN system product Approve by the Ethics Committee of Ruijin Hainan Hospital	18/22/18
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Achievement of Pre-Set Primary Clinical Endpoint in the RCT of Bioheart Bioresorbable Coronary Rapamycin-Eluting Scaffold in Patients With Coronary Heart Disease	16/22/16
Shanghai Bio-heart Biological Narrows H1 Loss to $17 Million	08/22/08
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	05/22/05
Shanghai Bio-Heart Biological Technology Co., Ltd. Approves Reappointment of Ernst & Young as Auditor	27/22/27
Shanghai Bio-Heart Biological Technology Co., Ltd. Finalizes Plans with Clinical Trial Investigators on the European Clinical Trial on Renal Artery Denervation Using Radial Access in Uncontrolled Hypertension	19/22/19
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Resignation of Jie Yin as A Non-Executive Director	12/22/12
Bio-Heart Narrows Per-Share Loss in 2021 on Lower R&D Expenses	21/22/21
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	18/22/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Other languages

Filters